曲妥珠单抗、帕妥珠单抗联合多西他赛治疗HER2突变晚期非小细胞肺癌患者:IFCT-1703 R2D2试验结果
IFCT-1703 R2D2是一项多中心、非随机II期研究,评估曲妥珠单抗、帕妥珠单抗联合多西他赛治疗既往接受过至少一线含铂治疗后进展的HER2突变晚期非小细胞肺癌患者。45例患者中,客观缓解率为29%,中位无进展生存期为6.8个月,3/4级治疗相关不良事件发生率为64%,无患者因毒性停药。作者认为该三联方案可行且有效,基于HER2抗体的策略应考虑用于此类患者。
要点
- 45例HER2突变晚期NSCLC患者接受曲妥珠单抗+帕妥珠单抗+多西他赛治疗,客观缓解率为29%。
- 中位无进展生存期为6.8个月,确认缓解患者的中位缓解持续时间为11个月。
- 3/4级治疗相关不良事件发生率为64%,最常见为中性粒细胞减少(33%)、腹泻(13%)和贫血(9%),无患者因毒性停药。
核心结论
- 曲妥珠单抗、帕妥珠单抗联合多西他赛治疗HER2突变经治晚期非小细胞肺癌可行且有效。
- 作者认为基于HER2抗体的策略应考虑用于此类患者。
研究设计与样本
- IFCT 1703-R2D2试验是一项多中心、非随机II期研究(NCT03845270)。
- 纳入HER2突变、晚期非小细胞肺癌、既往接受至少1线含铂治疗后进展的患者。
- 共45例患者入组并接受治疗。
- 给药方案:帕妥珠单抗负荷剂量840 mg,此后420 mg;曲妥珠单抗负荷剂量8 mg/kg,此后6 mg/kg;多西他赛75 mg/m2,每3周一次。
- 主要终点为客观缓解率。
主要发现
- 客观缓解率为29%(n=13),58%的患者疾病稳定(n=26)。
- 中位无进展生存期为6.8个月(95% CI,4.0至8.5)。
- 确认缓解患者(n=13)的中位缓解持续时间为11个月(95% CI,2.9至14.9)。
- 3/4级治疗相关不良事件发生率为64%,无患者因毒性停药。
- 最常见的≥3级治疗相关不良事件为中性粒细胞减少(33%)、腹泻(13%)和贫血(9%)。
关键数值与推荐
- 客观缓解率为29%(n=13)。
- 疾病稳定率为58%(n=26)。
- 中位无进展生存期为6.8个月(95% CI,4.0至8.5)。
- 确认缓解患者(n=13)的中位缓解持续时间为11个月(95% CI,2.9至14.9)。
- 3/4级治疗相关不良事件发生率为64%,无患者因毒性停药;常见≥3级事件为中性粒细胞减少(33%)、腹泻(13%)和贫血(9%)。
临床怎么用
- 作者认为曲妥珠单抗、帕妥珠单抗联合多西他赛方案可行且有效。
- 作者认为基于HER2抗体的策略应考虑用于HER2突变经治晚期非小细胞肺癌患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: HER2 exon 20 insertions and point mutations are oncogenic drivers found in 1%-2% of patients with non-small-cell lung cancer (NSCLC). No targeted therapy is approved for this subset of patients. We prospectively evaluated the effectiveness of the combination of two antibodies against human epidermal growth factor 2 (HER2 [HER2] trastuzumab and pertuzumab with docetaxel; trastuzumab and pertuzumab) and docetaxel. METHODS: The IFCT 1703-R2D2 trial is a multicenter, nonrandomized phase II study. Patients with HER2-mutated, advanced NSCLC who progressed after ≥ 1 platinum-based treatment were enrolled. Patients received pertuzumab at a loading dose of 840 mg and 420 mg thereafter; trastuzumab at an 8 mg/kg loading dose and 6 mg/kg thereafter; and docetaxel at a dose of 75 mg/m2 every 3 weeks. The primary outcome was the objective response rate (ORR). Other end points included the duration of response, progression-free survival, and safety (NCT03845270). RESULTS: Forty-five patients were enrolled and treated. The median age was 64.5 years (range, 31-84 years), 35% were smokers, 72% were females, 15% had an Eastern Cooperative Oncology Group performance status of 2, and 30% had brain metastases. The objective response rate was 29% (n = 13), and 58% had stable disease (n = 26). The median progression-free survival was 6.8 months (95% CI, 4.0 to 8.5). The median duration of response in patients with a confirmed response (n = 13) was 11 months (95% CI, 2.9 to 14.9). Grade 3/4 treatment-related adverse events were observed in 64% of the patients. No patient discontinued treatment because of toxicity. The most frequent grade ≥ 3 treatment-related adverse events were neutropenia (33%), diarrhea (13%), and anemia (9%). CONCLUSION: Triple therapy with trastuzumab, pertuzumab, and docetaxel is feasible and effective for HER2-mutated pretreated advanced NSCLC. These results highlight the effectiveness of the HER2 antibody-based strategy, which should be considered for these patients.
引用
- Mazieres J, Lafitte C, Ricordel C, et al. Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial. J Clin Oncol. 2022. PMID: 35073148. doi:10.1200/JCO.21.01455
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。